dipyridamole has been researched along with ketoconazole in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.94) | 18.7374 |
| 1990's | 1 (2.94) | 18.2507 |
| 2000's | 7 (20.59) | 29.6817 |
| 2010's | 19 (55.88) | 24.3611 |
| 2020's | 6 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA | 1 |
| Casciano, CN; Clement, RP; Johnson, WW; Wang, EJ | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Bakmiwewa, SM; Ball, HJ; Fatokun, AA; Hunt, NH; Payne, RJ; Tran, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Evans, WK; Stewart, DJ | 1 |
| Cripps, MC; Dahrouge, S; Davies, RA; Goel, R; Huan, S; Prosser, A; Soltys, K; Stewart, DJ; Tomiak, E; Yau, J | 1 |
| Abrahamsson, B; Dressman, JB; Goumas, K; Kalantzi, L; Persson, E; Polentarutti, B; Reppas, C | 1 |
| Kalantzi, L; Pastelli, E; Psachoulias, D; Reppas, C; Vertzoni, M | 1 |
| Beato, S; Butler, J; Goumas, K; Kalioras, V; Psachoulias, D; Reppas, C; Vertzoni, M | 1 |
| Busby, D; Butler, J; Dressman, J; Psachoulias, D; Reppas, C; Symillides, M; Vertzoni, M | 1 |
| Hasegawa, T; Higashino, H; Kataoka, M; Masaoka, Y; Matsui, R; Sakuma, S; Yamamoto, M; Yamashita, S | 1 |
| Augustijns, P; Brouwers, J; Kourentas, A; Reppas, C; Stavrinoudakis, N; Symillides, M; Symillidis, A; Vertzoni, M | 1 |
| Fukahori, M; Higashino, H; Ikemura, A; Kataoka, M; Kubota, A; Sakuma, S; Yamashita, S | 1 |
| Dressman, JB; Kambayashi, A; Yasuji, T | 1 |
| Ito, M; Koyama, H; Sugano, K; Terada, K | 1 |
| Amidon, GE; Amidon, GL; Matsui, K; Searls, AL; Sun, D; Takeuchi, S; Tsume, Y | 1 |
| Ehrick, JD; Hermans, A; Kesisoglou, F; Patel, S; Pennington, J; Sharma, N; Xia, B; Zhu, W | 1 |
| Ali, I; Brouwer, KLR; Khalid, S; Stieger, B | 1 |
| Hermans, A; Kesisoglou, F; Patel, S; Tsume, Y; Wang, M | 1 |
| Bermejo, M; Gonzalez-Alvarez, I; Hidalgo, IJ; Li, J; Silchenko, S; Spivey, N | 1 |
| Beran, K; Hirtreiter, C; Krollik, K; Kubas, H; Lehmann, A; Wagner, C | 1 |
| Kourentas, A; Statelova, M; Vertzoni, M | 1 |
| Higashino, H; Kataoka, M; Minami, K; Takagi, T; Yamashita, S | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
3 review(s) available for dipyridamole and ketoconazole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Non-chemotherapeutic agents that potentiate chemotherapy efficacy.
Topics: Adult; Amphotericin B; Animals; Antimetabolites; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Buthionine Sulfoximine; Calcium Channel Blockers; Calmodulin; Cardiotonic Agents; Child; Clinical Trials as Topic; Dipyridamole; Drug Evaluation; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Female; Humans; Ketoconazole; Male; Methionine Sulfoximine; Mice; Neoplasms; Nitroimidazoles; Xanthines | 1989 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
1 trial(s) available for dipyridamole and ketoconazole
| Article | Year |
|---|---|
Non-chemotherapeutic agents that potentiate chemotherapy efficacy.
Topics: Adult; Amphotericin B; Animals; Antimetabolites; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Buthionine Sulfoximine; Calcium Channel Blockers; Calmodulin; Cardiotonic Agents; Child; Clinical Trials as Topic; Dipyridamole; Drug Evaluation; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Female; Humans; Ketoconazole; Male; Methionine Sulfoximine; Mice; Neoplasms; Nitroimidazoles; Xanthines | 1989 |
31 other study(ies) available for dipyridamole and ketoconazole
| Article | Year |
|---|---|
Rational use of in vitro P-glycoprotein assays in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera | 2001 |
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
Topics: 3T3 Cells; Adrenergic Uptake Inhibitors; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Biological Transport, Active; Cell Line; Cell Separation; Cell Survival; Flow Cytometry; Fluorescent Dyes; Humans; Inhibitory Concentration 50; Mice; Protein Binding; Reserpine; Spectrometry, Fluorescence; Substrate Specificity; Time Factors | 2001 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
Topics: Animals; Dose-Response Relationship, Drug; Enzyme Inhibitors; HEK293 Cells; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Mice; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Substrate Specificity | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Pilot study of multiple chemotherapy resistance modulators plus epirubicin in the treatment of resistant malignancies.
Topics: Adjuvants, Pharmaceutic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antifungal Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Antitrichomonal Agents; Cyclosporine; Dipyridamole; Drug Resistance, Neoplasm; Epirubicin; Female; Humans; Immunosuppressive Agents; Ketoconazole; Male; Metronidazole; Middle Aged; Neoplasms; Pilot Projects; Tamoxifen; Vasodilator Agents | 1997 |
Canine intestinal contents vs. simulated media for the assessment of solubility of two weak bases in the human small intestinal contents.
Topics: Animals; Bile Acids and Salts; Buffers; Dipyridamole; Dogs; Duodenum; Fasting; Female; Food-Drug Interactions; Gastrointestinal Contents; Humans; Hydrogen-Ion Concentration; Jejunum; Ketoconazole; Lipids; Male; Polyethylene Glycols; Solubility; Species Specificity; Vitamin K | 2006 |
Estimation of intragastric solubility of drugs: in what medium?
Topics: Adult; Animals; Antifungal Agents; Dipyridamole; Dogs; Fasting; Felodipine; Female; Gastric Juice; Gastric Mucosa; Humans; Hydrogen-Ion Concentration; Ketoconazole; Kinetics; Miconazole; Osmolar Concentration; Pharmaceutical Preparations; Polyethylene Glycols; Solubility; Solutions; Stomach; Time Factors; Water | 2007 |
Precipitation in and supersaturation of contents of the upper small intestine after administration of two weak bases to fasted adults.
Topics: Adult; Antifungal Agents; Chemical Precipitation; Dipyridamole; Fasting; Female; Gastrointestinal Contents; Humans; Intestine, Small; Ketoconazole; Male; Phosphodiesterase Inhibitors; Solubility; Young Adult | 2011 |
An in vitro methodology for forecasting luminal concentrations and precipitation of highly permeable lipophilic weak bases in the fasted upper small intestine.
Topics: Antifungal Agents; Dipyridamole; Fasting; Humans; Imidazoles; Intestinal Absorption; Intestine, Small; Ketoconazole; Models, Biological; Permeability; Platelet Aggregation Inhibitors; Pyridines; Pyrrolidines; Solubility; TRPV Cation Channels; Urea | 2012 |
In vitro-in vivo correlation of the effect of supersaturation on the intestinal absorption of BCS Class 2 drugs.
Topics: Administration, Oral; Albendazole; Animals; Antineoplastic Agents; Calorimetry, Differential Scanning; Cytochrome P-450 CYP3A Inhibitors; Dipyridamole; Drug Stability; Gefitinib; In Vitro Techniques; Intestinal Absorption; Ketoconazole; Male; Quinazolines; Rats; Rats, Sprague-Dawley; Solubility; Solvents; Tubulin Modulators; Vasodilator Agents | 2014 |
An in vitro biorelevant gastrointestinal transfer (BioGIT) system for forecasting concentrations in the fasted upper small intestine: Design, implementation, and evaluation.
Topics: Dipyridamole; Fasting; Gastric Mucosa; Gastrointestinal Tract; In Vitro Techniques; Intestine, Small; Ketoconazole; Models, Biological; Ranitidine; Triazoles | 2016 |
Effects of gastric pH on oral drug absorption: In vitro assessment using a dissolution/permeation system reflecting the gastric dissolution process.
Topics: Administration, Oral; Albendazole; Body Fluids; Caco-2 Cells; Cell Line; Diclofenac; Dipyridamole; Gastric Mucosa; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Ketoconazole; Permeability; Pharmaceutical Preparations; Solubility; Water | 2016 |
Prediction of the precipitation profiles of weak base drugs in the small intestine using a simplified transfer ("dumping") model coupled with in silico modeling and simulation approach.
Topics: Administration, Oral; Computer Simulation; Dipyridamole; Gastric Emptying; Humans; Intestine, Small; Ketoconazole; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics | 2016 |
Effect of Seed Particles on Precipitation of Weak Base Drugs in Physiological Intestinal Conditions.
Topics: Animals; Chlorpromazine; Cinnarizine; Dipyridamole; Humans; Intestinal Absorption; Intestine, Small; Ketoconazole; Molecular Structure; Nitriles; Pioglitazone; Pyridines; Solubility; Thiazolidinediones | 2016 |
The impact of supersaturation level for oral absorption of BCS class IIb drugs, dipyridamole and ketoconazole, using in vivo predictive dissolution system: Gastrointestinal Simulator (GIS).
Topics: Administration, Oral; Animals; Chemical Precipitation; Computer Simulation; Dipyridamole; Drug Liberation; Gastrointestinal Tract; Intestinal Absorption; Ketoconazole; Mice, Inbred C57BL; Models, Biological; Solubility | 2017 |
Integration of Precipitation Kinetics From an In Vitro, Multicompartment Transfer System and Mechanistic Oral Absorption Modeling for Pharmacokinetic Prediction of Weakly Basic Drugs.
Topics: Administration, Oral; Chemical Precipitation; Computer Simulation; Dipyridamole; Drug Delivery Systems; Gastrointestinal Tract; Humans; Hydrogen-Ion Concentration; Ketoconazole; Kinetics; Models, Biological; Solubility | 2019 |
Effect of a Common Genetic Variant (p.V444A) in the Bile Salt Export Pump on the Inhibition of Bile Acid Transport by Cholestatic Medications.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; Baculoviridae; Bile Acids and Salts; Chemical and Drug Induced Liver Injury; Cholagogues and Choleretics; Cholestasis; Dipyridamole; Erythromycin; Glycocholic Acid; Ketoconazole; Kinetics; Membrane Transport Proteins; Polymorphism, Single Nucleotide; Sf9 Cells; Signal Transduction; Spodoptera; Taurocholic Acid; Transport Vesicles | 2019 |
The Introduction of a New Flexible In Vivo Predictive Dissolution Apparatus, GIS-Alpha (GIS-α), to Study Dissolution Profiles of BCS Class IIb Drugs, Dipyridamole and Ketoconazole.
Topics: Administration, Oral; Dipyridamole; Hydrogen-Ion Concentration; Intestinal Absorption; Ketoconazole; Pharmaceutical Preparations; Reproducibility of Results; Solubility | 2020 |
A differential equation based modelling approach to predict supersaturation and in vivo absorption from in vitro dissolution-absorption system (idas2) data.
Topics: Absorption, Physiological; Administration, Oral; Animals; Caco-2 Cells; Dipyridamole; Drug Liberation; Humans; Ketoconazole; Male; Models, Animal; Models, Biological; Rats; Solubility | 2021 |
Increasing the Robustness of Biopharmaceutical Precipitation Assays - Part I: Derivative UV Spectrophotometric Method Development for in-line Measurements.
Topics: Biological Products; Chromatography, High Pressure Liquid; Dipyridamole; Ketoconazole; Solubility | 2022 |
Simulation of Intraluminal Performance of Lipophilic Weak Bases in Fasted Healthy Adults Using DDDPlus
Topics: Administration, Oral; Adult; Computer Simulation; Dipyridamole; Humans; Intestinal Absorption; Intestine, Small; Ketoconazole; Models, Biological; Solubility | 2022 |
The effects of degree and duration of supersaturation on in vivo absorption profiles for highly permeable drugs, dipyridamole and ketoconazole.
Topics: Animals; Dipyridamole; Ketoconazole; Pharmaceutical Preparations; Rats; Solubility | 2023 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |